July 2019
Core topics in this month’s edition include:
- Hadlima (adalimumab-bwwd) – new biosimilar approval
- Kanjinti (trastuzumab-anns) – new biosimilar approval and launch
- Mvasi (bevacizumab-awwb) – new biosimilar approval and launch
- Ruxience (rituximab-pvvr) – new biosimilar approval
- Lyrica (pregabalin) – first time generic
Top